RECRUITING

Metabolism-Informed Care to Aid Alaska Native People to Quit Smoking (QUIT)

Talk to us

Conditions

Smoking Cessation

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to refine and pilot an intervention using the Nicotine Metabolite Ratio (NMR) to inform the selection of pharmacologic treatment to increase smoking abstinence among Alaska Native and American Indian people. This is a single-arm pilot trial to assess and improve acceptability and feasibility.

Official Title

Metabolism-Informed Care to Aid Alaska Native People to Quit Smoking (QUIT): Pilot Intervention and Assessment of Barriers and Facilitators of Implementation

Quick Facts

Study Start:2024-08-26
Study Completion:2025-05
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06556238

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Alaska Native or American Indian person by self-report
  2. * eligible for or already receiving services at Southcentral Foundation (SCF)
  3. * age 18 years or older
  4. * daily smoking in the past 30-days
  5. * if other nicotine or tobacco products are used, cigarettes are main product used
  6. * planning to schedule an appointment with the Quit Tobacco Program to seek smoking cessation treatment in the next 30 days
  7. * willing to make a quit attempt within 30 days of enrollment in the Quit Tobacco Program
  8. * willing to have a blood test to inform their treatment
  9. * willing to try a pharmacologic treatment
  10. * willing to provide a saliva sample
  11. * has phone service
  12. * has access to broadband internet on mobile phone at home, work, or other location
  13. * has an Android or iPhone mobile phone compatible with the Smokerlyzer app
  1. * Participated in the prior study phase
  2. * participated in a cessation program during the past 3 months
  3. * their provider has not approved varenicline in their referral to the Quit Tobacco Program
  4. * has history of serious hypersensitivity or skin reactions to varenicline
  5. * has bleeding disorder or is currently receiving cancer treatment
  6. * questionable capacity or impaired decision-making capacity

Contacts and Locations

Study Contact

Todd Takeno, MA
CONTACT
907-729-8623
ttakeno@SouthcentralFoundation.com

Principal Investigator

Georgia J Michlig, PhD
PRINCIPAL_INVESTIGATOR
Southcentral Foundation

Study Locations (Sites)

Anchorage Native Primary Care Center
Anchorage, Alaska, 99508
United States

Collaborators and Investigators

Sponsor: Southcentral Foundation

  • Georgia J Michlig, PhD, PRINCIPAL_INVESTIGATOR, Southcentral Foundation

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-08-26
Study Completion Date2025-05

Study Record Updates

Study Start Date2024-08-26
Study Completion Date2025-05

Terms related to this study

Additional Relevant MeSH Terms

  • Smoking Cessation